Glycyrrhizinic acid, a major bioactive compound found in licorice root (Glycyrrhiza glabra), has a long history of use in traditional medicine, but its use to support the hepatic (liver) system is also backed by scientific research. Several studies have investigated glycyrrhizin and its derivatives for their hepatoprotective effects, particularly in managing liver diseases such as hepatitis and liver inflammation.

Clinical trials, especially in Japan and China, have shown that glycyrrhizin can reduce elevations of liver enzymes in patients with chronic hepatitis, indicating improved liver function. The proposed mechanisms include anti-inflammatory, antioxidant, immunomodulatory, and antiviral activities. Glycyrrhizin has demonstrated the ability to inhibit the replication of hepatitis viruses and suppress liver fibrosis in experimental models. Furthermore, it may reduce liver cell apoptosis and oxidative stress.

Although the evidence is promising, most of the clinical studies are small or conducted in specific populations, and concerns exist about safety at high doses or with prolonged use (notably, potential for pseudoaldosteronism, hypertension, and hypokalemia). As such, the overall evidence rating is moderate, and glycyrrhizin is considered a scientifically supported, but not definitive, ingredient for liver support.